{"name":"Shanghai Antengene Corporation Limited","slug":"shanghai-antengene-corporation-limited","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxQdDJqZko5NS1lZWlQMndhQWpkQ2tYekpoNHRXV3k4dDdLUHB4Yy12TkNwMzhQaDdSLTRLdWJpbEhXbm5tMTE5SWstVGppSkI1aWlTMEJOV1pNWVA4d0dtaE0wSHJKd1lnSmo0WXhHSTlzMUc4ZjcwTVVYOVBXckRyMGZiQW1lMHl2SDVvbFRkbVIzQXpXeng3UnZoZC1ZNnNP?oc=5","date":"2026-03-04","type":"deal","source":"BioWorld News","summary":"UCB inks $1.1B deal for Antengene’s autoimmune bispecific TCE - BioWorld News","headline":"UCB inks $1.1B deal for Antengene’s autoimmune bispecific TCE","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-25","type":"deal","source":"The Manila Times","summary":"Junshi Biosciences Announces Strategic Collaboration with Antengene to Evaluate Combination Therapy with JS207 (PD-1/VEGF BsAb) and ATG-037 (Oral CD73 Inhibitor) - The Manila Times","headline":"Junshi Biosciences Announces Strategic Collaboration with Antengene to Evaluate Combination Therapy with JS207 (PD-1/VEG","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwJBVV95cUxQMjJfNjI2cEZBZTZtREl2bFdubkZOZnk0UzdUd0U0UTJ5Qnp6Q19vMVJaQlFzaWRTSjFGVG05YUhQYTR3a3ppRWRhLUc1bEotVkVkZXlnZ2V1cHVkS2ItUTF1UV9MbHRvUWU4Umt0UjVTM1RNUXctQ0pkOXNjWDk4UmNSVHVWRkZvbjB3ZkJETHFOb2g1cmtMcy1uRWlqaTFsNGduajRKMjF2WXc1OWlLRUhFUVFjNjM5cG5qV3JZVWdKVFRaWmlIMDR3SlBfLUJRV1B1WC1UMmdjR1g5MkFNeW1mTnlJanRjYmc4RHJ0dV9YSzZBbnB2emdkNHgtXzVyMnhWcENSSUc1MG5PRkN3OWw2T09pQURxSjZKLW5jOFJXbjBtSFdKbW0weTZscFdfekV4ZXBvdVFESnhibFNmb2FGalNCMW8wdTlIOW01TQ?oc=5","date":"2026-02-24","type":"deal","source":"PR Newswire","summary":"Antengene Announces Clinical Collaboration with Junshi Biosciences to Explore the Synergistic Potential of ATG-037 (Oral CD73 Inhibitor) In Combination with JS207 (PD-1/VEGF BsAb) - PR Newswire","headline":"Antengene Announces Clinical Collaboration with Junshi Biosciences to Explore the Synergistic Potential of ATG-037 (Oral","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9AFBVV95cUxPMzk1Q1NiYXRxNjBCUEEzY3NDRmU0ckJyakF3blRscU41cUdQSC11aTd4bmd3Q2tNTEs4eUVSRUhrSmMwSFVmcGtVazA5SHBSNXdfeXJfWUpMSTRYUFFfSXJ0eVk0NURnbjhVUzBFd3pIVG1VT3hqMWd6bG1wWC1pVWlXanNEMlZWT2k3WFJZMWZ0UzMzMFpVcHFKdmFoN3VFa3pnanhGbkdYQUFkdnFkazZqXzVnd04wdThVWVJCeFFQOTl2SUJXMFMyUGphYzVQOThHdEx6ZzhuM0ZPUHZwZWRZUFg3VTNETGRfYjY4Sm5sVHhQ?oc=5","date":"2026-01-15","type":"trial","source":"PR Newswire","summary":"Antengene Presents at JPM: Strong Clinical Data Update and Strategic Focus on Next-Generation ADCs and TCEs - PR Newswire","headline":"Antengene Presents at JPM: Strong Clinical Data Update and Strategic Focus on Next-Generation ADCs and TCEs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowJBVV95cUxPQkItWjlCTkNrSnNRY2tJX2VRQUFTMFBENzFwdUd0U05kUzhaVFBLVThNdFJTYnRKeS1Yd3BROFVoemNTYm9PTmpNLWxjckRWVXduSFIxUmpfSzV3Y2dhREZwZWZkUHRtOWVtZVBNTEkzRDZicWpCZExSVFduaFRZZTRqNWVrbG5HZXAtWTZQR05YbG5wbE5XRFNSMHVZMkYyQXJGa3pzdC1LNzdBeWdIRDNycHVVY3pvS3JFclgyd0RfSkczZ0oteFI2QnNFb1BrRGlEaExMSXNVRkNFRlhQRDRxVzViVXN3dndHNzMyMFhoaHhJVDQyODhCYXppYlpvZEc1Z3FvUkt6LVFJWndOUV80b1I3aThzUkVaUDY3QWwxU1k?oc=5","date":"2025-08-19","type":"pipeline","source":"PR Newswire","summary":"Antengene's ATG-022 (CLDN18.2 ADC) Granted Breakthrough Therapy Designation for the Treatment of Gastric/Gastroesophageal Junction Adenocarcinoma - PR Newswire","headline":"Antengene's ATG-022 (CLDN18.2 ADC) Granted Breakthrough Therapy Designation for the Treatment of Gastric/Gastroesophagea","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwJBVV95cUxQbGNyY0FoUE5aVnR3M1pEMFZkcC1MU1BTRDVuTnJOYXlMYmt5VUJfNXFFYjBidjZGazJCYXN2ZE5kU2poV1l6TWlHTlpQSE1WV1BpUFhvQjFUUFU4QTJTblljbWJLMy0zZUdJdE9VOVRUZnMzOFZGVklfU2N6UE9IVkhOczBsSkpWbHlSZnl0ek5GNjN2YVJrMlJaandxLTZDMHlHT09uYzhlU3NDaWpPUEVkeXBQYXU5enR5VVE3ejktNGNOY2xOZ1lSOGhWUkRKRlZ5ODdSZm9za3hnbmZfN0NhcEI3X2Rfbk4zLUdUUmVHVERuQ01kLTZEMlpxWGFKQUZCcEt3UmxIM1ZfS1N4TnU1WUxkdW91RlZHZU5RVQ?oc=5","date":"2025-05-20","type":"deal","source":"PR Newswire","summary":"Antengene Enters into a Global Clinical Collaboration with MSD to Evaluate ATG-022 (CLDN18.2 ADC) In Combination with KEYTRUDA® (pembrolizumab) - PR Newswire","headline":"Antengene Enters into a Global Clinical Collaboration with MSD to Evaluate ATG-022 (CLDN18.2 ADC) In Combination with KE","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgJBVV95cUxOVDdWa2VTajBPcmdTTWx0ODFZcllWZ3BUbUhiQzdWWnlKbmplMTdsNGpVVEVpazhIeXJaYU5lRnd5UXBiRzhDRE1WWjZNQ08tMWprQ3EtTmxMN3RIcXUxRFlITWpvaFlLb1VrMHRNR2RnNnBCSGdfTFNvbHc3ZmdsVFJXaUpCNkZ3ejNxQU1PQWxpdjJudllSZTlqVVhnczZYdVpXZ01YOXVPQ0lSSXdMNlFTUlJoRVExMXNERkFYalhaWDBvSURKQUFlVHVTQ01na05oOC1ZZ29TcW9PR19TTmcxS2dfc1VFaVBuS1R0ODZ2VXB3WUtYcEtXZzhya3NuU0NsZ0QtMl9wZ3QtUHJ2blFraEN5SDFhMXllOC1LWVVidUEwTkNWNHZ1RGI4dw?oc=5","date":"2023-08-10","type":"deal","source":"PR Newswire","summary":"Antengene Enters into Commercialization Partnership with Hansoh Pharma for First/Only-in-Class XPO1 Inhibitor XPOVIO®(selinexor) in the Mainland of China - PR Newswire","headline":"Antengene Enters into Commercialization Partnership with Hansoh Pharma for First/Only-in-Class XPO1 Inhibitor XPOVIO®(se","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2023-05-31","type":"trial","source":"GlobeNewswire","summary":"B-Cell Lymphoma Clinical Trial Pipeline Insights: - GlobeNewswire","headline":"B-Cell Lymphoma Clinical Trial Pipeline Insights:","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWkFVX3lxTE9YZzdOT1NpTEMxaHhhck92MVQ3bC1oNnE3cmdDbHRYaDRfMEYtTWd2QmNrb1BrdE1tVEp0ZnRrUkptWGhibUlOVU9lbG1zY0Y2OHpsbjFjcWxOdw?oc=5","date":"2020-11-19","type":"pipeline","source":"TradingView","summary":"6996 Stock Price and Chart — HKEX:6996 - TradingView","headline":"6996 Stock Price and Chart — HKEX:6996","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}